Replies to post #81002 on Biotech Values

[mcbio]

Re: TRGT depression data/seizures

Looking at the PDR, the rate of seizures during clinical trials for Citalopram was 0.3% of patients treated, vs. 0.5% of patients treated with placebo.

If the TRGT data included one seizure event, I would not be too concerned so long as their sample size was sufficiently large. I haven't looked at the study, so if this was a relatively small PII with less than 200 enrolled, caution would be advised.

Thanks for the response. There were 265 patients in the intent to treat number. The PR didn't break this down between patients receiving TC-5214 + citalopram versus those receiving placebo + citalopram. If we split that number, you have 1 out of 132 patients, or 0.7%, in the active arm having a seizure. That is pretty much in line with the numbers for frequency of seizures in citalopram or placebo treated patients historically. So, I don't think this is necessarily bad news for TRGT's drug. Also, the seizure could be tied to citalopram and not TC-5214.